Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: Experimental validation with implications for Parkinson's therapy

Neuroscience

Volumn 199, Issue , 2011, Pages 303-317

  Sultana, Z ^a,b   Paleologou, K E ^c   Al Mansoori, K M ^c   Ardah, M T ^c   Singh, N ^a   Usmani, S ^a   Jiao, H ^d,e   Martin, F L ^d   Bharath, M M S ^f   Vali, S ^a   El Agnaf, O M A ^c  

^a CELLWORKS GROUP INC   (United States)

^b Cellworks Research India Pvt Ltd   (India)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e NINGXIA MEDICAL UNIVERSITY   (China)

^f NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

synuclein; Dopaminergic neuron; In silico; Oligomers; Parkinson's disease; Protein aggregation

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; CUPRIC ION; DOPAMINE; MUTANT PROTEIN; OLIGOMER; PROTEASOME; THREONINE;

ARTICLE; CELL SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; LYSOSOME; MOLECULAR DYNAMICS; MOLECULAR MODEL; NEUROPROTECTION; NITRATION; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; VALIDATION STUDY;

ALPHA-SYNUCLEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; COMET ASSAY; DOPAMINERGIC NEURONS; HUMANS; LEWY BODIES; MODELS, NEUROLOGICAL; PARKINSON DISEASE; USER-COMPUTER INTERFACE;

EID: 83055180511     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.10.018     Document Type: Article

References (61)

1. Amer D.A., Irvine G.B., El-Agnaf O.M. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res 2006, 173:223-233.
2. Asanuma M., Miyazaki I., Diaz-Corrales F.J., Ogawa N. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama 2004, 58:221-233.
3. Bellucci A., Navarria L., Zaltieri M., Falarti E., Bodei S., Sigala S., Battistin L., Spillantini M., Missale C., Spano P. Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. J Neurochem 2011, 116(4):588-605.
4. Beyer K., Ariza A. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Curr Med Chem 2008, 15:2748-2759.
5. Bodles A.M., El-Agnaf O.M., Greer B., Guthrie D.J., Irvine G.B. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci Lett 2004, 359:89-93.
6. Burke W.J. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease. Curr Drug Targets CNS Neurol Disord 2003, 2:143-148.
7. Chafekar S.M., Hoozemans J.J., Zwart R., Baas F., Scheper W. Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal 2007, 12:2245-2254.
8. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destée A. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
9. Chinta S.J., Andersen J.K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 2006, 41:1442-1448.
10. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998, 17:7151-7160.
11. Contestabile A., Monti B., Contestabile A., Ciani E. Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. Curr Med Chem 2003, 10:2147-2174.
12. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009, 106(31):13010-13015.
13. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008, 283:9089-9100.
14. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
15. Ding T.T., Lee S.J., Rochet J.C., Lansbury P.T. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41:10209-10217.
16. El-Agnaf O.M., Paleologou K.E., Greer B., Abogrein A.M., King J.E., Salem S.A., Fullwood N.J., Benson F.E., Hewitt R., Ford K.J., Martin F.L., Harriott P., Cookson M.R., Allsop D. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004, 18:1315-1317.
17. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006, 20:419-425.
18. El-Agnaf O.M., Walsh D.M., Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol 2003, 2:461-462.
19. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001, 10:1847-1851.
20. Foltynie T., Brayne C., Barker R.A. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002, 249:138-145.
21. Gosavi N., Lee H.J., Lee J.S., Patel S., Lee S.J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 2002, 277:48984-48992.
22. Hermida-Ameijeiras A., Méndez-Alvarez E., Sánchez-Iglesias S., Sanmartín-Suárez C., Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int 2004, 45:103-116.
23. Jagatha B., Mythri R.B., Vali S., Bharath M.M. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008, 44:907-917.
24. Kabuta T., Furuta A., Aoki S., Furuta K., Wada K. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 2008, 283(35):23731-23738.
25. Kaushik P., Gorin F., Vali S. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comput Neurosci 2007, 22:147-160.
26. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
27. Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. {alpha}-Synuclein aggregation and ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 2009, 284(15):10211-10222.
28. Krishnan S., Chi E.Y., Wood S.J., Kendrick B.S., Li C., Garzon-Rodriguez W., Wypych J., Randolph T.W., Narhi L.O., Biere A.L., Citron M., Carpenter J.F. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 2003, 42:829-837.
29. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
30. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418:291.
31. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002, 322:1089-1102.
32. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 2001, 15(6):916-926.
33. Lee H.J., Khoshaghideh F., Patel S., Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004, 24:1888-1896.
34. Martin F.L., Cole K.J., Orme M.H., Grover P.L., Phillips D.H., Venitt S. The DNA repair inhibitors hydroxyurea and cytosine arabinoside enhance the sensitivity of the alkaline single-cell gel electrophoresis ('comet') assay in metabolically-competent MCL-5 cells. Mutat Res 1999, 445:21-43.
35. Martin F.L., Williamson S.J., Paleologou K.E., Hewitt R., El-Agnaf O.M., Allsop D. Fe(II)-induced DNA damage in α-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the comet assay. J Neurochem 2003, 87:620-630.
36. McNaught K.S., Olanow C.W. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006, 27:530-545.
37. Mizuta I., Satake W., Nakabayashi Y., Ito C., Suzuki S., Momose Y., Nagai Y., Oka A., Inoko H., Fukae J., Saito Y., Sawabe M., Murayama S., Yamamoto M., Hattori N., Murata M., Toda T. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006, 15:1151-1158.
38. Morris A.M., Finke R.G. Alpha-synuclein aggregation variable temperature and variable pH kinetic data: a re-analysis using the Finke-Watzky 2-step model of nucleation and autocatalytic growth. Biophys Chem 2009, 140:9-15.
39. Olanow C.W., Perl D.P., DeMartino G.N., McNaught K.S. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004, 3:496-503.
40. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000, 20:6048-6054.
41. Paleologou K.E., Kragh C.L., Mann D.M., Salem S.A., Al-Shami R., Allsop D., Hassan A.H., Jensen P.H., El-Agnaf O.M. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1101.
42. Pals P., Lincoln S., Manning J., Heckman M., Skipper L., Hulihan M., Van den Broeck M., De Pooter T., Cras P., Crook J., Van Broeckhoven C., Farrer M.J. Alpha-synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 2004, 56:591-595.
43. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M.R. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
44. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., Duvoisin R.C. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996, 274:1197-1199.
45. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
46. Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J., Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 2005, 102:10427-10432.
47. Raichur A., Vali S., Gorin F. Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease. Neuroscience 2006, 142:859-870.
48. Sandal M., Valle F., Tessari I., Mammi S., Bergantino E., Musiani F., Brucale M., Bubacco L., Samorì B. Conformational equilibria in monomeric alpha-synuclein at the single-molecule level. PLoS Biol 2008, 6(1):e6.
49. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
50. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
51. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem 2003, 278:11753-11759.
52. Sugeno N., Takeda A., Hasegawa T., Kobayashi M., Kikuchi A., Mori F., Wakabayashi K., Itoyama Y. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 2008, 283(34):23179-23188.
53. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000, 97:11869-11874.
54. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 2001, 276:10737-10744.
55. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001, 276:44284-44296.
56. Vali S., Chinta S.J., Peng J., Sultana Z., Singh N., Sharma P., Sharada S., Andersen J.K., Bharath M.M. Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data. Free Radic Biol Med 2008, 45:1290-1301.
57. Vali S., Mythri R.B., Jagatha B., Padiadpu J., Ramanujan K.S., Andersen J.K., Gorin F., Bharath M.M. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007, 149:917-930.
58. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
59. Wang X., Moualla D., Wright J.A., Brown D.R. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J Neurochem 2010, 113(3):704-714.
60. Wright J.A., Wang X., Brown D.R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J 2009, 23(8):2384-2393.
61. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.